Jun 4, 2018 Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting
May 25, 2018 Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone
May 22, 2018 Oncolytics Biotech® Has Applied to List its Common Shares on Nasdaq and Announces Share Consolidation
May 17, 2018 Oncolytics Biotech® Announces Collaboration Between Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study
